Results 81 to 90 of about 38,595 (290)

GLP-1Rimmunostaining in colon.

, 2018
GLP-1R positive nerve fibres (Abcam antibody, left panels) and PGP9.5 (right panels) in mucosal sigmoid colon biopsy specimens, from top—control, middle and bottom–IBD, magnification x40.
Mike Fox (5309444), Marco Sinisi (56682), Ayesha Akbar (4918297), Anthony MacQuillan (5309447), Ben Jones (554472), Tom Quick (5309438), Praveen Anand (42856), Steve R. Bloom (5309441), Uma Anand (1418002), Yuri E. Korchev (1298694), Yiangos Yiangou (61513)   +10 more
core   +2 more sources

Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study. [PDF]

Sci Rep
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce incidence of cardiovascular events in type 2 diabetes (T2D) patients. Yet, the impact of GLP-1RAs on coronary lesion progression and cardiovascular outcomes after coronary stent implantation ...
Zeng H, Hu J, Zhuo Y, Wang M, Gao L, Tang Z, Zhang J, Yin P, Gu J, Wang C.   +9 more
europepmc   +2 more sources

Unveiling Gut Homeostasis Disruption in Sepsis: Towards an Integrated Mechanistic and Translational Roadmap

Cell Proliferation, EarlyView.
Elucidating the contribution of gut‐organ axes will provide new insights for developing combined therapeutic strategies against sepsis‐associated multiple organ dysfunction. ABSTRACT Sepsis, a life‐threatening clinical syndrome precipitated by a maladaptive host response to infection, is associated with substantial morbidity and high mortality rates ...
Yichen Bao, Lin Qi, Guijun Zou, Xingpeng Yang, Yizhao Ma, Zhifu Li, Xiaohui Du, Pengyue Zhao   +7 more
wiley   +1 more source

Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists

Diabetes & Vascular Disease Research
The newfound knowledge in type 2 diabetes (T2D) during the past decade for the sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) is wealthy in favorable results for key patient-important outcomes ...
Kyriakos Kintzoglanakis, Christos Diamantis, Anargiros Mariolis, Stavroula A Paschou   +3 more
doaj   +1 more source

GLP-1R undergoes agonist-induced palmitoylation.

, 2019
(A) Total input (“I”) and palmitoylated (“P”) SNAP-GLP-1R fractions from CHO SNAP-GLP-1R cells treated with vehicle (“Veh”) or 100 nM exendin-4 (“Ex4”) for 10 min.
Aylin Hanyaloglu (7289285), Hannah Norman (7289273), Ivan R. Corrêa Jr (7289279), Alejandra Tomas (4768059), Thomas Burgoyne (3329148), Davide Calebiro (217846), Teresa Buenaventura (4768041), Asuka Inoue (52011), Ben Jones (554472), Guy A. Rutter (150009), Jak Grimes (7289288), Abigail Walker (7289282), Stavroula Bitsi (7289264), Affiong I. Oqua (7289270), Emma R. McGlone (7289276), Stephen R. Bloom (7289294), Andrey S. Klymchenko (1268781), Zsombor Koszegi (7289291), William E. Laughlin (4747062), Zekun Lyu (7289267)   +19 more
core   +1 more source

Interventions for binge eating disorder in adults with type 2 diabetes: A systematic review

Diabetic Medicine, EarlyView.
Abstract Aims Binge eating disorder frequently co‐occurs with type 2 diabetes, creating a dual burden that may complicate both psychological well‐being and glycaemic management. Evidence on the effectiveness of health interventions in this population is limited.
Pernille Fiil Nybo, Nikolaj Vang Nielsen, Julie Drotner Mouritsen, Michael Einar Røder, Jakob Linnet   +4 more
wiley   +1 more source

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Ankle Fracture Open Reduction and Internal Fixation

Foot & Ankle Orthopaedics
Research Type: Level 3 - Retrospective cohort study, Case-control study, Meta-analysis of Level 3 studies Introduction/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are quickly growing in popularity as effective tools in the management of ...
Joshua Morningstar BS, Bradley Lauck BA, Nicholas Bank MD, Trapper Lalli MD   +3 more
doaj   +1 more source

Figure 6: Proposed Mechanisms for a GLP-1RA-Induced Anti-Atherosclerotic Effect

, 2019
Proposed model illustrating how long-acting GLP-1RAs could reduce atherosclerotic burden.
Bidda Rolin (304752), Lotte Bjerre Knudsen (1523629), Jane Nøhr (662593), Ib Klewe (6820634), Camilla Ingvorsen (6820640), Robert Augustin (6820637), Klaus S. Frederiksen (3016914), Joseph Polex-Wolf (6820643), Jacob Hecksher-Sørensen (76243), Günaj Rakipovski (846823)   +9 more
core   +1 more source

Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. Materials and Methods In this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐
Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan   +9 more
wiley   +1 more source

An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes [PDF]

Advancing therapy in T2DM with injectables, i.e., basal insulin (BI) and GLP‐1 receptor agonists (GLP‐1RAs) is recommended after the failure of oral glucose lowering agents (OGLAs), BI alone, or BI in combination with OGLAs, especially in persons with ...
Owens, David R., Horowitz, Michael, Porcellati, Francesca, Perseghin, Gianluca, Fanelli, Carmine G., Lucidi, Paola, Bolli, Geremia B.   +6 more
core   +3 more sources